DelveInsight has launched a new report on Fabry Disease Market
The Fabry Disease market report provides an edge while developing business strategies, by understanding trends shaping and driving the Fabry Disease market report.
Fabry Disease Overview
Fabry disease (FD) is a devastating, progressive, inherited condition caused by lysosomal dysfunction linked to chromosome X and mutations in the GLA gene located in chromosome Xq22.1 which encodes the alpha-galactosidase A (AGA) enzyme.
Request for free sample copy- https://www.delveinsight.com/sample-request/fabry-disease-market
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Fabry Disease Treatment Market
The primary disease process starts in infancy, or even as early as in the fetal stage of development. In FD, lysosomal storage and cellular dysfunction are believed to trigger a cascade of events including cellular death, compromised energy metabolism, small vessel injury, K(Ca) channel dysfunction in endothelial cells, oxidative stress, impaired autophagosome maturation, tissue ischemia and, importantly, development of irreversible cardiac and renal tissue fibrosis.
Fabry Disease Market Disease
Fabry Disease is classified as the Type 1 classic and Type 2 later-onset on the basis of phenotype of the disease. Both sub-types result in renal failure, and/or cardiac disease, and early death. Type 2 later-onset Fabry Disease is more frequent as compared to Type 1 classic Fabry Disease.
Fabry Disease Market Companies
- Shire/ Takeda
- Amicus Therapeutics
- And many others
As per DelveInsight assessments, the market size of Fabry disease (FD) in the 7MM was found to USD 833.74 Million in 2017, for the study period (2017-2030). Among 7MM, United States accounts for the highest market size of Fabry disease in comparison with EU5 and Japan.
Currently, the therapeutic market size of Fabry disease is mainly accounted by Enzyme Replacement Therapy including (Fabrazyme, Replagal) and Chemical Chaperone Therapy (Migalastat, Amigal) are commonly used interventions. Moreover, symptomatic pain therapy for chronic neuropathic pain including Carbamazepine, Gabapentin, Phenytoin, Pregabalin, Tricyclic antidepressants, Duloxetine, Venlafaxine and for acute pain, the therapies including Intravenous lidocaine, Tramadol, Morphine, Oxycodone, Ibuprofen, Diclofenac) are in extensive use in the US market.
Fabry Disease Market Report Scope
- The report covers the descriptive overview of Fabry Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Fabry Disease epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Fabry Disease are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Fabry Disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Fabry Disease market
Request for a free sample copy- https://www.delveinsight.com/sample-request/fabry-disease-market
Table of content
- Key Insights
- Executive Summary of Fabry Disease
- Competitive Intelligence Analysis for Fabry Disease
- Fabry Disease Market Overview at a Glance
- Fabry Disease Disease Background and Overview
- Patient Journey
- Fabry Disease Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Unmet Needs
- Key Endpoints of Fabry Disease Treatment
- Marketed Products
- Emerging Therapies
- Fabry Disease: Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview of Fabry Disease
- KOL Views
- Market Drivers
- Market Barriers
- DelveInsight Capabilities
- About DelveInsight
What will be the Key Questions Answered?
- What was the Fabry Disease market share (%) distribution in 2017 and how it would look like in 2030?
- What would be the Fabry Disease total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Fabry Disease market size during the forecast period (2017-2030)?
- At what CAGR, the Fabry Disease market is expected to grow in 7MM during the forecast period (2017-2030)?
- What would be the Fabry Disease market outlook across the 7MM during the forecast period (2017-2030)?
- What would be the Fabry Disease market growth till 2030, and what will be the resultant market Size in the year 2030?
- How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Fabry Disease market
- To understand the future market competition in the Fabry Disease market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Fabry Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Fabry Disease market
- To understand the future market competition in the Fabry Disease market
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States